Dermorphin: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข5 clinical studies cited
- โขOverall evidence level: low
- โข5 research gaps identified
Research Studies
Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei
Montecucchi PC, de Castiglione R, Piani S, et al. (1981) โข International Journal of Peptide and Protein Research
Original identification and sequencing of dermorphin from frog skin, establishing its heptapeptide structure and the presence of a D-amino acid residue.
Key Findings
- First isolation and characterization of dermorphin
- Determined complete amino acid sequence
- Identified unusual D-alanine at position 2
Limitations: Initial characterization study; limited pharmacological data
Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin
Broccardo M, Erspamer V, Falconieri Erspamer G, et al. (1981) โข British Journal of Pharmacology
Comprehensive pharmacological characterization of dermorphin showing potent opioid activity in multiple bioassay systems with high selectivity for mu receptors.
Key Findings
- Demonstrated potent analgesic activity in vivo
- Established mu-opioid receptor selectivity
- Showed dermorphin is more potent than morphine
Limitations: Animal model studies only; no human data
Characterisation and visualisation of [3H]dermorphin binding to mu opioid receptors in the rat brain
Bhargava HN, Gulati A (1990) โข Neuropeptides
Developed radiolabeled dermorphin as a tool for visualizing and characterizing mu-opioid receptors in the rat brain using autoradiography.
Key Findings
- High selectivity of [3H]dermorphin for mu receptors confirmed
- Mapped mu receptor distribution in rat brain
- Combined high selectivity and affinity in a natural peptide agonist
Limitations: In vitro and ex vivo autoradiography only
Spinal action of dermorphin, an extremely potent opioid peptide from frog skin
Stevens CW, Yaksh TL (1986) โข Brain Research
Evaluated the spinal analgesic action of dermorphin administered intrathecally in rats, demonstrating its extreme potency compared to morphine.
Key Findings
- Intrathecal dermorphin produced dose-dependent analgesia
- Potency 3-5000 times greater than morphine in various tests
- Effects blocked by naloxone confirming opioid mechanism
Limitations: Animal study with central route of administration
D-Alanine in the frog skin peptide dermorphin is derived from L-alanine in the precursor
Kreil G, Barra D, Simmaco M, et al. (1989) โข Science
Demonstrated that the D-alanine residue in dermorphin is biosynthesized from L-alanine through post-translational isomerization, a novel finding for vertebrate peptides.
Key Findings
- D-Ala derived from L-Ala in the precursor protein
- First evidence of enzymatic L-to-D isomerization in vertebrates
- Gene encodes L-amino acid that is post-translationally modified
Limitations: Mechanistic study; exact isomerase enzyme not identified
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
0View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขNo human clinical trials conducted
- โขLimited pharmacokinetic data from systemic administration
- โขBlood-brain barrier penetration studies incomplete
- โขLong-term safety profile not established
- โขMechanism of post-translational D-amino acid isomerization not fully elucidated
Research Overview#
Dermorphin has been the subject of extensive preclinical research since its discovery in 1981. The literature encompasses receptor binding studies, in vivo analgesic evaluations, structure-activity relationship analyses, biosynthetic investigations, and the development of dermorphin-derived pharmacological tools. Despite this rich preclinical evidence base, no human clinical trials have been conducted with dermorphin itself.
Key Preclinical Studies#
Discovery and Characterization#
The landmark study by Montecucchi and colleagues in 1981 established the amino acid sequence of dermorphin as Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, isolated from methanol extracts of Phyllomedusa sauvagei skin. Concurrently, Broccardo, Erspamer, and colleagues published comprehensive pharmacological characterization showing that dermorphin was orders of magnitude more potent than morphine in standard opioid bioassays including guinea pig ileum and mouse vas deferens preparations, with clear mu-receptor selectivity.
Receptor Binding and Selectivity#
Multiple studies have confirmed dermorphin's exceptional selectivity for the mu-opioid receptor. Binding competition assays using [3H]dermorphin demonstrated Ki values in the low nanomolar range at mu receptors, with 100- to 1000-fold lower affinity at delta and kappa subtypes. Autoradiographic mapping studies by Bhargava and Gulati (1990) visualized [3H]dermorphin binding throughout the rat brain, with highest densities in the thalamic nuclei, periaqueductal gray, nucleus accumbens, and spinal cord dorsal horn.
Analgesic Efficacy#
Stevens and Yaksh (1986) demonstrated that intrathecal dermorphin in rats produced dose-dependent antinociception with extraordinary potency, estimated at 3,000 to 5,000 times that of morphine on a molar basis in certain test paradigms. The analgesic effects were completely reversed by the opioid antagonist naloxone, confirming an opioid receptor-mediated mechanism. Duration of action exceeded that of equianalgesic doses of morphine, consistent with the enhanced metabolic stability conferred by the D-amino acid residue.
Biosynthesis and D-Amino Acid Origin#
The discovery by Kreil and colleagues (1989) that dermorphin's D-alanine is derived from L-alanine through a post-translational enzymatic process was published in Science and represented a paradigm shift in understanding of vertebrate peptide biochemistry. This finding established that vertebrates possess enzymatic machinery for L-to-D amino acid isomerization, a capability previously thought to be restricted to bacteria and invertebrates.
Analog Development#
The development of dermorphin-based affinity labels has provided tools for identifying and characterizing mu-opioid receptor binding sites at the molecular level. Researchers synthesized photoaffinity and electrophilic analogs that covalently bind to the receptor, enabling biochemical characterization and purification studies. These tools contributed to the eventual cloning and structural characterization of the mu-opioid receptor.
Systematic Reviews and Meta-Analyses#
A comprehensive review of dermorphin and related frog skin opioid peptides has noted their continued relevance as pharmacological tools and potential templates for analgesic drug design. Reviews highlight the renewed interest in dermorphin-type peptides for developing peripherally restricted mu-opioid agonists and biased agonists with improved therapeutic windows.
Evidence Quality Assessment#
The overall evidence quality for dermorphin is low by clinical standards, as all data are preclinical. Within the preclinical domain, the evidence is generally of moderate to high quality, with well-controlled pharmacological experiments replicated across multiple independent laboratories. The receptor binding data are consistent and reproducible, and the analgesic efficacy data are robust across multiple pain models and species. However, the complete absence of human clinical data limits the translatability of these findings.
Ongoing Research Directions#
Current research on dermorphin and its analogs focuses on several areas:
- Development of dermorphin-derived biased agonists that preferentially activate G-protein signaling over beta-arrestin recruitment, potentially yielding analgesics with reduced side effects
- Design of peripherally restricted dermorphin analogs for treating peripheral pain without central opioid effects
- Use of dermorphin-based peptides as targeting moieties for tumor-directed drug delivery, exploiting mu-opioid receptor overexpression in certain cancers
- Investigation of dermorphin-related peptides from additional amphibian species for novel pharmacological activities
Related Reading#
Frequently Asked Questions About Dermorphin
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.